Medicus Pharma
MDCXMedicus Pharma Ltd. is a clinical-stage, multi-strategy biotechnology company focused on developing novel therapeutic assets through Phase 2 proof-of-concept.
Table of contents
Earnings
Next report
Aug 10, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Medicus Pharma Ltd. is a clinical-stage, multi-strategy biotechnology company focused on developing novel therapeutic assets through Phase 2 proof-of-concept. The company utilizes a capital-efficient model to advance disruptive medical technologies, primarily targeting non-melanoma skin cancers and advanced prostate cancer, with the intent to out-license or partner with established pharmaceutical firms for late-stage development.
A clinical-stage developer of niche therapeutic delivery systems and hormone therapies targeting multi-billion dollar markets in dermatology and urology.
Questions, answered.
- What is Medicus Pharma's market cap?
- Medicus Pharma (MDCX) has a market capitalization of $18.0M and trades on XNAS.
- Who are Medicus Pharma's competitors?
- Medicus Pharma's key competitors include CytomX Therapeutics, Inc., Azitra Inc, Soligenix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Medicus Pharma partner with?
- Medicus Pharma's notable partners include University of Pittsburgh, Helix Nanotechnologies, Inc., Gorlin Syndrome Alliance, and others.
- What subsidiaries does Medicus Pharma have?
- Medicus Pharma's subsidiaries include SkinJect Inc., Antev Ltd..
- Where is Medicus Pharma headquartered?
- Medicus Pharma is headquartered in Canada. It has been publicly traded since 2023.